Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.53 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.44 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.41 |
| ▸ | TLR2 | O60603 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
| ▸ | NMT2 | O60551 | 1/20 | 0.34 |
| ▸ | NMT1 | P30419 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20800966 | 0.93 | GLP1R (0.52) | GLP1RLPAR3LPAR1TLR2FOLH1 | |
| SCHEMBL26524106 | 0.93 | GLP1R (0.47) | GLP1RLPAR3LPAR1TLR2TSHR | |
| SCHEMBL20370974 | 0.90 | GLP1R (0.52) | GLP1RLPAR3LPAR1TLR2TSHR | |
| SCHEMBL18708284 | 0.89 | GLP1R (0.46) | GLP1RLPAR3LPAR1TLR2TSHR | |
| SCHEMBL18708278 | 0.88 | GLP1R (0.48) | GLP1RLPAR3LPAR1TLR2TSHR | |
| SCHEMBL26524137 | 0.87 | GLP1R (0.45) | GLP1RLPAR3LPAR1TLR2TSHR | |
| SCHEMBL23714552 | 0.84 | GLP1R (0.51) | GLP1RLPAR3LPAR1TLR2TSHR | |
| SCHEMBL18715649 | 0.83 | GLP1R (0.54) | GLP1RLPAR3LPAR1TLR2FOLH1 | |
| SCHEMBL26524111 | 0.83 | GLP1R (0.47) | GLP1RLPAR3LPAR1TLR2TSHR | |
| SCHEMBL22923670 | 0.83 | GLP1R (0.73) | GLP1RLPAR3LPAR1TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355651-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20180195069-A1 | Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2018-07-12 | — | — | US | disclosed |
| US-20180195070-A1 | Compositions and Methods for Inhibiting Gene Expression of LPA | Arrowhead Pharmaceuticals, Inc. | 2018-07-12 | — | — | US | disclosed |
| US-9932586-B2 | Compositions and methods for inhibiting gene expression of LPA | Arrowhead Pharmaceuticals, Inc. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170096665-A1 | Compositions and Methods for Inhibiting Gene Expression of LPA | Arrowhead Pharmaceuticals, Inc. | 2017-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355651-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885LPAR3 549/4885LPAR1 389/4885 |
| US-20180195069-A1 | Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use | SERPINA2, SERPINC1, SERPINA3 | GLP1R 4004/4885LPAR3 3281/4885LPAR1 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.